



MediciNova

A small company with big potential

MediciNova has five Phase II clinical trials ongoing in progressive multiple sclerosis (MS), Lou Gehrig's Disease (ALS) and addiction. Its lead programme, MN-166 in Phase IIb for progressive MS, has shown a statistically significant improvement on neurodegenerative endpoints (including brain volume loss) and has an extensive safety database.

MN-166, a potential blockbuster for progressive MS

MN-166 has been on the market in Japan for 25 years with a safety database of 3.2 million patients. In a Phase II trial in relapsing-remitting multiple sclerosis (RRMS), MN-166 had a statistically significant reduction in brain volume loss (p=0.035) and conversion of acute lesions into persistent black holes (a sign of irreversible demyelination and axonal loss) (p=0.004). However, it missed the primary endpoint in that trial (number of new active lesions), which may indicate that it will work better in the more neurodegenerative types of MS than inflammatory (RRMS).

Progressive MS, a major unmet medical need

PPMS and SPMS are major unmet medical needs. The only drug approved for either indication is Novantrone, a chemotherapeutic, for the treatment of SPMS though its cumulative dosing is limited due to cardiotoxicity. PPMS and SPMS have the potential to be as big a market as RRMS (\$18bn+ in 2014), as 90% of those with RRMS eventually progress to SPMS over 20-25 years.

The rest of the pipeline is not to be ignored

MN-166 is also in Phase II for addiction, where it demonstrated statistically significant reductions in certain symptoms (eg craving, perspiration, hot flashes) in previous trials, as well as ALS. MN-001, which has anti-fibrotic and anti-inflammatory properties, has had Phase II protocols for NASH and IPF approved by the FDA and there will be an update on these programmes later this year.

Valuation: EV ~\$70m

The current valuation is supported by the pipeline, which has multiple shots on goal and a potential blockbuster in MN-166 for progressive forms of MS. MediciNova has \$11.7m in cash, which should fund it for over a year (it is been burning ~\$9m pa). Upcoming near-term catalysts could be MS and ALS data presentations at the American Academy of Neurology (AAN) on 21-23 April. Other major catalysts (ALS data in 2016 and MS data in 2017) could provide considerable upside, if positive.


Consensus estimates						
Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	6.0	(4.0)	(0.19)	N/A	N/A	N/A
12/14	N/A	(9.2)	(0.38)	N/A	N/A	N/A
12/15e	N/A	(9.4)	(0.33)	N/A	N/A	N/A
12/16e	N/A	(9.9)	(0.29)	N/A	N/A	N/A

Source: MediciNova

Pharma & biotech

26 March 2015





Share details Code MNOV Listing NASDAQ Shares in issue 24.62m

Business description

MediciNova is a US-based biopharmaceutical company focused on developing MN-166 for progressive MS, where it is in a Phase IIb trial. It also has a broad pipeline with Phase II programmes for ALS, addiction, NASH and IPF.

Bull

- With an EV of ~\$69m, success in even one indication would provide upside.
- MN-166 has shown statistically significant neuroprotective properties in a previous MS patient trial, indicating potential efficacy in progressive MS.
- MN-001 has had Phase II protocols approved for IPF and NASH, two priority areas for large pharma companies.

Bear

- MN-166 has previously missed the primary endpoint (number of new active lesions) in a trial of RRMS patients.
- Progressive forms of MS have been difficult to treat in the past and there have been many failed trials from a variety of agents.
- MediciNova does not have the funding to move all its programmes itself and is dependent on partners and potentially dilutive financings.

Analysts				
Maxim Jacobs, CFA	+1 (646) 653-7027			
Dr Mick Cooper	+44 (0)20 3077 5734			

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Services only. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited (4794244). www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by MediciNova and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research as on the report of the securities and sustralia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" for investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscribe, or underwine any securities. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provide or information purposes only and should not b